Inhibition of AMPK signalling by doxorubicin: At the crossroads of the cardiac responses to energetic, oxidative, and genotoxic stress

Cardiovascular Research

Volumn 95, Issue 3, 2012, Pages 290-299

  Gratia, Séverine ^a,b   Kay, Laurence ^a,b   Potenza, Lucia ^c   Seffouh, Amal ^a,b   Novel Chate, Valérie ^a,b   Schnebelen, Coralie ^a,b   Sestili, Piero ^c   Schlattner, Uwe ^a,b   Tokarska Schlattner, Malgorzata ^a,b  

^a Domaine Universitaire   (France)

^b INSERM   (France)

^c UNIVERSITY OF URBINO   (Italy)

Author keywords

Adenosine 5' monopnophosphate activated protein kinase; Anthracyclines; Cardiac energetics; Cardiac signalling; Cardiotoxicity; MK2206

Indexed keywords

ACETYL COENZYME A CARBOXYLASE; DNA DEPENDENT PROTEIN KINASE; DOXORUBICIN; GENOMIC DNA; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MAMMALIAN TARGET OF RAPAMYCIN; MITOCHONDRIAL DNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE; STRESS ACTIVATED PROTEIN KINASE; TUBULIN; ANTINEOPLASTIC ANTIBIOTIC; MTOR PROTEIN, RAT; PROTEIN KINASE INHIBITOR; TARGET OF RAPAMYCIN KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL ENERGY; CELL SURVIVAL; CONTROLLED STUDY; DNA DAMAGE; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GENOTOXICITY; HEART FUNCTION; HEART PERFUSION; HEART RATE; HEART VENTRICLE ENDDIASTOLIC PRESSURE; IMMUNOBLOTTING; IMMUNOPRECIPITATION; ISOLATED HEART; LIMIT OF QUANTITATION; NEGATIVE FEEDBACK; NONHUMAN; OXIDATIVE STRESS; PHENOTYPE; PRIORITY JOURNAL; RAT; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SURVIVAL FACTOR; UPREGULATION; ANIMAL; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; ENERGY METABOLISM; ENZYMOLOGY; GENETICS; HEART DISEASE; HEART MUSCLE CELL; MALE; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHOSPHORYLATION; TIME; WISTAR RAT;

ACETYL-COA CARBOXYLASE; AMP-ACTIVATED PROTEIN KINASES; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; DISEASE MODELS, ANIMAL; DNA DAMAGE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; ENERGY METABOLISM; ENZYME ACTIVATION; HEART DISEASES; MALE; MITOGEN-ACTIVATED PROTEIN KINASES; MYOCYTES, CARDIAC; OXIDATIVE STRESS; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RATS, WISTAR; SIGNAL TRANSDUCTION; TIME FACTORS; TOR SERINE-THREONINE KINASES;

EID: 84871696392     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvs134     Document Type: Article

References (55)

1. Gianni L, Herman EH, Lipshultz SE, Minotti G, Sarvazyan N, Sawyer DB. Anthracycline cardiotoxicity: from bench to bedside. J Clin Oncol 2008;26:3777-3784.
2. Tokarska-Schlattner M, Zaugg M, da Silva R, Lucchinetti E, Schaub MC, Wallimann T et al. Acute toxicity of doxorubicin on isolated perfused heart: response of kinases regulating energy supply. Am J Physiol Heart Circ Physiol 2005;289:H37-H47. (Pubitemid 40934080)
3. Cai C, Lothstein L, Morrison RR, Hofmann PA. Protection from doxorubicin-induced cardiomyopathy using the modified anthracycline N-benzyladriamycin-14-valerate (AD 198). J Pharmacol Exp Ther 2010;335:223-230.
4. Konishi M, Haraguchi G, Ohigashi H, Ishihara T, Saito K, Nakano Y et al. Adiponectin protects against doxorubicin-induced cardiomyopathy by anti-apoptotic effects through AMPK up-regulation. Cardiovasc Res 2011;89:309-319.
5. Hardie DG. AMP-activated protein kinase: an energy sensor that regulates all aspects of cell function. Genes Dev 2011;25:1895-1908.
6. Neumann D, Schlattner U, Wallimann T. A molecular approach to the concerted action of kinases involved in energy homoeostasis. Biochem Soc Trans 2003;31: 169-174. (Pubitemid 36241421)
7. Viollet B, Horman S, Leclerc J, Lantier L, Foretz M, Billaud M et al. AMPK inhibition in health and disease. Crit Rev Biochem Mol Biol 2010;45:276-295.
8. Shaw RJ. LKB1 and AMP-activated protein kinase control of mTOR signalling and growth. Acta Physiol (Oxf) 2009;196:65-80.
9. Sengupta S, Peterson TR, Sabatini DM. Regulation of the mTOR complex 1 pathway by nutrients, growth factors, and stress. Mol Cell 2010;40:310-322.
10. Ikeda Y, Sato K, Pimentel DR, Sam F, Shaw RJ, Dyck JR et al. Cardiac-specific deletion of LKB1 leads to hypertrophy and dysfunction. J Biol Chem 2009;284:35839-35849.
11. Dolinsky VW, Chan AY, Robillard Frayne I, Light PE, Des Rosiers C, Dyck JR. Resveratrol prevents the prohypertrophic effects of oxidative stress on LKB1. Circulation 2009;119:1643-1652.
12. Couturier K, Servais S, Koubi H, Sempore B, Sornay-Mayet MH, Cottet-Emard JM et al. Metabolic characteristics and body composition in a model of anti-obese rats (Lou/C). Obes Res 2002;10:188-195. (Pubitemid 135687509)
13. Lortet S, Heckmann M, Aussedat J, Ray A, Vincent M, Sassard J et al. Alteration of cardiac energy state during development of hypertension in rats of the Lyon strain: a 31P-NMR study on the isolated rat heart. Acta Physiol Scand 1993;149:311-321. (Pubitemid 23344103)
14. Guidi C, Potenza L, Sestili P, Martinelli C, Guescini M, Stocchi L et al. Differential effect of creatine on oxidatively-injured mitochondrial and nuclear DNA. Biochim Biophys Acta 2008;1780:16-26. (Pubitemid 350216949)
15. Tokarska-Schlattner M, Lucchinetti E, Zaugg M, Kay L, Gratia S, Guzun R et al. Early effects of doxorubicin in perfused heart: transcriptional profiling reveals inhibition of cellular stress response genes. Am J Physiol Regul Integr Comp Physiol 2010;298: R1075-R1088.
16. Tokarska-Schlattner M, Zaugg M, Zuppinger C, Wallimann T, Schlattner U. New insights into doxorubicin-induced cardiotoxicity: the critical role of cellular energetics. J Mol Cell Cardiol 2006;41:389-405. (Pubitemid 44362995)
17. Rajagopalan S, Politi PM, Sinha BK, Myers CE. Adriamycin-induced free radical formation in the perfused rat heart: implications for cardiotoxicity. Cancer Res 1988;48: 4766-4769.
18. L'Ecuyer T, Sanjeev S, Thomas R, Novak R, Das L, Campbell W et al. DNA damage is an early event in doxorubicin-induced cardiac myocyte death. Am J Physiol Heart Circ Physiol 2006;291:H1273-H1280. (Pubitemid 44343672)
19. Lebrecht D, Setzer B, Ketelsen UP, Haberstroh J, Walker UA. Time-dependent and tissue-specific accumulation of mtDNA and respiratory chain defects in chronic doxorubicin cardiomyopathy. Circulation 2003;108:2423-2429. (Pubitemid 37413552)
20. Hardie DG. Role of AMP-activated protein kinase in the metabolic syndrome and in heart disease. FEBS Lett 2008;582:81-89. (Pubitemid 350297243)
21. Suter M, Riek U, Tuerk R, Schlattner U, Wallimann T, Neumann D. Dissecting the role of 5'-AMP for allosteric stimulation, activation, and deactivation of AMP-activated protein kinase. J Biol Chem 2006;281:32207-32216. (Pubitemid 46036775)
22. Xie Z, Dong Y, Scholz R, Neumann D, Zou MH. Phosphorylation of LKB1 at serine 428 by protein kinase C-zeta is required for metformin-enhanced activation of the AMP-activated protein kinase in endothelial cells. Circulation 2008;117:952-962. (Pubitemid 351272593)
23. Ruderman NB, Xu XJ, Nelson L, Cacicedo JM, Saha AK, Lan F et al. AMPK and SIRT1: a long-standing partnership?. Am J Physiol Endocrinol Metab 2010;298:E751-E760.
24. Kovacic S, Soltys CL, Barr AJ, Shiojima I, Walsh K, Dyck JR. Akt activity negatively regulates phosphorylation of AMP-activated protein kinase in the heart. J Biol Chem 2003; 278:39422-39427. (Pubitemid 37248497)
25. Soltys CL, Kovacic S, Dyck JR. Activation of cardiac AMP-activated protein kinase by LKB1 expression or chemical hypoxia is blunted by increased Akt activity. Am J Physiol Heart Circ Physiol 2006;290:H2472-H2479. (Pubitemid 43846078)
26. Hahn-Windgassen A, Nogueira V, Chen CC, Skeen JE, Sonenberg N, Hay N. Akt activates the mammalian target of rapamycin by regulating cellular ATP level and AMPK activity. J Biol Chem 2005;280:32081-32089. (Pubitemid 41361813)
27. Horman S, Vertommen D, Heath R, Neumann D, Mouton V, Woods A et al. Insulin antagonizes ischemia-induced Thr172 phosphorylation of AMP-activated protein kinase alpha-subunits in heart via hierarchical phosphorylation of Ser485/491. J Biol Chem 2006;281:5335-5340. (Pubitemid 43847626)
28. Dyck JR, Lopaschuk GD. AMPK alterations in cardiac physiology and pathology: enemy or ally? J Physiol 2006;574:95-112. (Pubitemid 43905800)
29. Bozulic L, Surucu B, Hynx D, Hemmings BA. PKBalpha/Akt1 acts downstream of DNA-PK in the DNA double-strand break response and promotes survival. Mol Cell 2008;30:203-213. (Pubitemid 351626686)
30. Bozulic L, Hemmings BA. PIKKing on PKB: regulation of PKB activity by phosphorylation. Curr Opin Cell Biol 2009;21:256-261.
31. Lee ER, Kim JY, Kang YJ, Ahn JY, Kim JH, Kim BW et al. Interplay between PI3K/Akt and MAPK signaling pathways in DNA-damaging drug-induced apoptosis. Biochim Biophys Acta 2006;1763:958-968.
32. Gabrielson K, Bedja D, Pin S, Tsao A, Gama L, Yuan B et al. Heat shock protein 90 and ErbB2 in the cardiac response to doxorubicin injury. Cancer Res 2007;67:1436-1441. (Pubitemid 46383368)
33. Hirai H, Sootome H, Nakatsuru Y, Miyama K, Taguchi S, Tsujioka K et al. MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol Cancer Ther 2010;9: 1956-1967.
34. Du J, Guan T, Zhang H, Xia Y, Liu F, Zhang Y. Inhibitory crosstalk between ERK and AMPK in the growth and proliferation of cardiac fibroblasts. Biochem Biophys Res Commun 2008;368:402-407.
35. Esteve-Puig R, Canals F, Colome N, Merlino G, Recio JA. Uncoupling of the LKB1-AMPKalpha energy sensor pathway by growth factors and oncogenic BRAF. PLoS ONE 2009;4:e4771.
36. Kehat I, Molkentin JD. Extracellular signal-regulated kinase 1/2 (ERK1/2) signaling in cardiac hypertrophy. Ann N Y Acad Sci 2010;1188:96-102.
37. Lou H, Danelisen I, Singal PK. Involvement of mitogen-activated protein kinases in adriamycin-induced cardiomyopathy. Am J Physiol Heart Circ Physiol 2005;288: H1925-H1930. (Pubitemid 40418022)
38. Hardie DG. AMPK and Raptor: matching cell growth to energy supply. Mol Cell 2008; 30:263-265. (Pubitemid 351615323)
39. Huang J, Manning BD. A complex interplay between Akt, TSC2 and the two mTOR complexes. Biochem Soc Trans 2009;37:217-222.
40. Schlattner U, Tokarska-Schlattner M, Wallimann T. Mitochondrial creatine kinase in human health and disease. Biochim Biophys Acta 2006;1762:164-180. (Pubitemid 43006023)
41. Tokarska-Schlattner M, Dolder M, Gerber I, Speer O, Wallimann T, Schlattner U. Reduced creatine-stimulated respiration in doxorubicin challenged mitochondria: particular sensitivity of the heart. Biochim Biophys Acta 2007;1767:1276-1284. (Pubitemid 350017745)
42. Wakasugi S, Fischman AJ, Babich JW, Callahan RJ, Elmaleh DR, Wilkinson R et al. Myocardial substrate utilization and left ventricular function in adriamycin cardiomyopathy. J Nucl Med 1993;34:1529-1535. (Pubitemid 23254351)
43. Braith RW. Role of exercise in rehabilitation of cancer survivors. Pediatr Blood Cancer 2005;44:595-599. (Pubitemid 40629207)
44. Danz ED, Skramsted J, Henry N, Bennett JA, Keller RS. Resveratrol prevents doxorubicin cardiotoxicity through mitochondrial stabilization and the Sirt1 pathway. Free Radic Biol Med 2009;46:1589-1597.
45. Chicco AJ, Schneider CM, Hayward R. Voluntary exercise protects against acute doxorubicin cardiotoxicity in the isolated perfused rat heart. Am J Physiol Regul Integr Comp Physiol 2005;289:R424-R431. (Pubitemid 41060497)
46. Mitra MS, Donthamsetty S, White B, Latendresse JR, Mehendale HM. Mechanism of protection of moderately diet restricted rats against doxorubicin-induced acute cardiotoxicity. Toxicol Appl Pharmacol 2007;225:90-101. (Pubitemid 350017834)
47. Mitra MS, Donthamsetty S, White B, Mehendale HM. High fat diet-fed obese rats are highly sensitive to doxorubicin-induced cardiotoxicity. Toxicol Appl Pharmacol 2008; 231:413-422.
48. Saks V, Favier R, Guzun R, Schlattner U, Wallimann T. Molecular system bioenergetics: regulation of substrate supply in response to heart energy demands. J Physiol 2006; 577:769-777. (Pubitemid 44873644)
49. Vichalkovski A, Gresko E, Hess D, Restuccia DF, Hemmings BA. PKB/AKT phosphorylation of the transcription factor Twist-1 at Ser42 inhibits p53 activity in response to DNA damage. Oncogene 2010;29:3554-3565.
50. Wencker D, Chandra M, Nguyen K, Miao W, Garantziotis S, Factor SM et al. A mechanistic role for cardiac myocyte apoptosis in heart failure. J Clin Invest 2003;111: 1497-1504. (Pubitemid 38063282)
51. Taniyama Y, Walsh K. Elevated myocardial Akt signaling ameliorates doxorubicin-induced congestive heart failure and promotes heart growth. J Mol Cell Cardiol 2002;34:1241-1247. (Pubitemid 35244397)
52. Razeghi P, Sharma S, Ying J, Li YP, Stepkowski S, Reid MB et al. Atrophic remodeling of the heart in vivo simultaneously activates pathways of protein synthesis and degradation. Circulation 2003;108:2536-2541. (Pubitemid 37444418)
53. Kobayashi S, Volden P, Timm D, Mao K, Xu X, Liang Q. Transcription factor GATA4 inhibits doxorubicin-induced autophagy and cardiomyocyte death. J Biol Chem 2010; 285:793-804.
54. Lai KP, Leong WF, Chau JF, Jia D, Zeng L, Liu H et al. S6K1 is a multifaceted regulator of Mdm2 that connects nutrient status and DNA damage response. EMBO J 2010;29: 2994-3006.
55. Zhu W, Soonpaa MH, Chen H, Shen W, Payne RM, Liechty EA et al. Acute doxorubicin cardiotoxicity is associated with p53-induced inhibition of the mammalian target of rapamycin pathway. Circulation 2009;119:99-106.